Highlights
- •We aim to adapt guidelines to every day Internal Medicine practice
- •Good guidelines published during last 5 years will be preferably selected
- •Some summaries could only remark lack of evidence for aged patients
Abstract
Keywords
Introduction
- Seto K
- Matsumoto K
- Fujita S
- Kitazawa T
- Amin R
- Hatakeyama Y
- et al.
- Zhou H
- Zhang S
- Sun X
- Yang D
- Zhuang X
- Guo Y
- et al.
- Li Q
- Li X
- Wang J
- Liu H
- Kwong JS
- Chen H
- et al.
- Ena J
- Gómez-Huelgas R
- Romero-Sánchez M
- Gaviria AZ
- Calzada-Valle A
- Varela-Aguilar JM
- et al.
2. Methodology
https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf.

2.1 The documents to be delivered
2.2 Selection of the topics
2.3 Selection of the elaborating team for the adaptation task
2.4 Selection of the clinical questions
2.5 Selection of CPG used for adaptation?
https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf.
- a)the mean score is at least 3 for each item (i.e. at least 9 in Domain 1 AND at least 24 in Domain 3)
- b)at least 50% threshold for each of these domains [calculated as follow: (Obtained score – Minimum possible score)/(Maximum possible score – Minimum possible score) x 100% is reached.
2.6 Selection of recommendations from the original existing CPG
- a)an answer to PICO (a recommendation) is detected there and is of high quality. This recommendation is adapted.
- b)an answer to PICO does not appear in existing CPG so there is nothing to adapt. The lack of recommendation should be highlighted in the final report.
- c)the recommendation answering the PICO is of poor quality due to - Outdated literature (it can be detected by chance if a task force member knows relevant new evidence not included in the original CPG) and/or - lack of recommendation strength. The task force will decide if this recommendation can be used with some explanation or should not be used.
- d)there are differences in recommendations across various guidelines and no consensus recommendation can be made (see 2.7 below).
2.7 Ways to manage any disagreements between recommendations from CPG of the same quality
- a)select one of them
- b)include all with explanation for the disagreement particularly if all recommendations are directly related to Internal medicine patients (see 2.8 below).
2.8 Focus of recommendations on the internal medicine patients (e.g. age, frailty and multimorbidity appropriately taken into account)
- a)Was the problem of multiple comorbidities considered in the text of original CPG?
- b)What are the implications of multiple comorbidities and older age in the specific clinical situation (the topic of CPG)?
- c)Should any good practice statements considering these specific populations be formulated?
- d)Were drug adverse effects and drug interactions considered in the original CPG?
- a)The task force should consider the most frequently occurring combination of comorbidities that coincide with this single disease (i.e., with cardiac diseases: diabetes, COPD, obesity or renal failure; with COPD: tobacco dependence, alcohol abuse or arteriosclerosis).
- b)The task force should assess whether the guideline literature review includes original articles that take into account aged individuals with multiple comorbidities or using multiple medications (e.g.: higher risk of hypoglycemia in older patients, patients with renal disease using beta-blockers). If such original articles are included in the CPG the task force could either deliver a summary of them or only mention that there are original studies addressing these two issues. The latter option is preferable.
- c)As some PICOs can be answered only if drug side effects and interactions are appropriately considered, the task force should assess whether the original CPG literature review includes articles that discuss drug side effects and interactions.
2.9 Editorial process and dissemination
2.9.1 Structure of the report
- a)a brief introduction highlighting the rationale for the article
- b)a brief mention of the CPG considered for adaptation (rejected and accepted).
- c)all necessary explanations for the discrepancy between guidelines and/or recommendation limitations
- d)a list of PICOs and related recommendations (with the strength and quality of evidence from each of the CPG selected)
- e)a short summary of the answers to the PICO questions accompanied, when possible, with a flow chart or clinical pathway
- f)a short discussion of the issues related to internal medicine practice, emphasizing the aspects needed for better knowledge and research
- g)if possible a short discussion with some remarks on implementation, but as healthcare provision is varied across the EFIM member countries a single suggested method of implementation is unlikely to be useful
- h)references (see 2.9.3 below).
2.9.2 External validation
- a)EFIM Executive Committee
- b)the editor of the European Journal of Internal Medicine.
2.9.3 References
2.9.4 Supportive tools
2.10 Management of the potential conflicts of interest
3. Discussion
- Li Q
- Li X
- Wang J
- Liu H
- Kwong JS
- Chen H
- et al.
https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf.
4. Conclusion
Declaration of Competing Interests
Acknowledgment
Appendix. Supplementary materials
References
- Quality assessment of clinical practice guidelines using the AGREE instrument in Japan: a time trend analysis.Plos One. 2019 May 2; 14 (eCollection 2019)e0216346https://doi.org/10.1371/journal.pone.0216346
- Lipid management for coronary heart disease patients: an appraisal of updated international guidelines applying appraisal of guidelines for research and evaluation II-clinical practice guideline appraisal for lipid management in coronary heart disease.J Thorac Dis. 2019 Aug; 11: 3534-3546https://doi.org/10.21037/jtd.2019.07.71
- Grading quality of evidence and strength of recommendations.BMJ. 2004; 328: 1490
- GRADE guidelines: 1. Introduction: GRADE evidence profiles and summary of findings tables.J Clin Epidemiol. 2011; 64: 383-394
- World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance.J Clin Epidemiol. 2016 Apr; 72: 98-106https://doi.org/10.1016/j.jclinepi.2014.10.011
- Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements.BMJ Open. 2019 Aug 24; 9e026677https://doi.org/10.1136/bmjopen-2018-026677
- Systematic review of clinical practice guidelines recommendations about primary cardiovascular disease prevention for older adults.BMC Fam Pract. 2015 Aug 20; 16: 104https://doi.org/10.1186/s12875-015-0310-1
- Prevalence of chronic diseases and multimorbidity among the elderly population in Sweden.Am J Public Health. 2008 Jul; 98: 1198-1200https://doi.org/10.2105/AJPH.2007.121137
- Epidemiology of multimorbidity and implications for health care, research, and medical education: a crosssectional study.Lancet. 2012; 380: 37-43https://doi.org/10.1016/S0140-6736(12)60240-2
- International group for reducing inappropriate medication use & polypharmacy (IGRIMUP): position statement and 10 recommendations for action.Drugs Aging. 2018 Jul; 35: 575-587https://doi.org/10.1007/s40266-018-0554-2
- Deprescribing in older people: why it matters in routine clinical practice.Pol Arch Intern Med. 2018 Apr 30; 128: 197-199https://doi.org/10.20452/pamw.4255.Epub 2018 Apr 27
- Reperfusion treatment in acute myocardial infarction in elderly patients.Kardiol Pol. 2018; 76: 830-837https://doi.org/10.5603/KP.a2018.0092.Epub 2018 Apr 10
- Diabetes and obesity working group of the spanish society of internal medicine. Hyperglycemia management in patients admitted to internal medicine in Spain: a point-prevalence survey examining adequacy of glycemic control and guideline adherence.EJIM. 2015 Jul; 26: 392-398https://doi.org/10.1016/j.ejim.2015.04.020
- For the AGREE collaborative group. Guideline development in Europe: an international comparison.Int J Technol Assess Health Care. 2000; 16: 1036-1046
https://www.agreetrust.org/wp-content/uploads/2017/12/AGREE-II-Users-Manual-and-23-item-Instrument-2009-Update-2017.pdf.
- Delphi-RAND consensus of the Spanish society of internal medicine on the controversies in anticoagulant therapy and prophylaxis in medical diseases.Intrombin Project Rev Clin Esp. 2018; 218: 358-371https://doi.org/10.1016/j.rce.2018.04.006
- Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study.Ann Intern Med. 2009; 151: 854-860
- How to Integrate multiple comorbidities in guideline development: article 10 in integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.Proc Am Thorac Soc. 2012; 9: 274-281
- A framework for crafting clinical practice guidelines that are relevant to the care and management of people with multimorbidity.J Gen Intern Med. 2014; 29: 670-679
- The prevalence of disease clusters in older adults with multiple chronic diseases–a systematic literature review.PloS ONE. 2013; 8: e79641
- Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance.JAMA. 2005; 294: 716-724